Literature DB >> 18485049

Prevalence and significance of vitamin D deficiency in multiple myeloma patients.

Ashraf Badros, Olga Goloubeva, Evangelos Terpos, Todd Milliron, Maria R Baer, Elizabeth Streeten.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18485049     DOI： 10.1111/j.1365-2141.2008.07214.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  21 in total

1.  A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia.

Authors:  Karthik Nath; Vibooshini Ganeshalingam; Barbara Ewart; Elizabeth Heyer; Kerrianne Watt; Andrew Birchley; John Casey; Hock Choong Lai; Edward Morris; Georgina Hodges
Journal:  Support Care Cancer       Date:  2019-06-21       Impact factor: 3.603

2.  Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.

Authors:  James Wang; Kyle A Udd; Aleksandra Vidisheva; Regina A Swift; Tanya M Spektor; Eric Bravin; Emad Ibrahim; Jonathan Treisman; Mohammed Masri; James R Berenson
Journal:  Support Care Cancer       Date:  2016-02-23       Impact factor: 3.603

3.  Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature.

Authors:  Digant Gupta; Pankaj G Vashi; Kristen Trukova; Christopher G Lis; Carolyn A Lammersfeld
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

4.  Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.

Authors:  D M Greenfield; E Boland; Y Ezaydi; R J M Ross; S H Ahmedzai; J A Snowden
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

Review 5.  Updates on osteonecrosis of the jaw.

Authors:  Junro Yamashita; Laurie K McCauley; Catherine Van Poznak
Journal:  Curr Opin Support Palliat Care       Date:  2010-09       Impact factor: 2.302

Review 6.  Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.

Authors:  Muhammad Asad Fraz; Faiza Hassan Warraich; Sami Ullah Warraich; Muhammad Junaid Tariq; Zabih Warraich; Ali Younas Khan; Muhammad Usman; Awais Ijaz; Pavan Tenneti; Adeela Mushtaq; Faisal Akbar; Zaina Shahid; Zeeshan Ali; Hafiz Muhammad Fazeel; Cesar Rodriguez; Aboo Nasar; Ali McBride; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2019-02-27       Impact factor: 6.312

Review 7.  Vitamin D in the cancer patient.

Authors:  Kurt A Kennel; Matthew T Drake
Journal:  Curr Opin Support Palliat Care       Date:  2013-09       Impact factor: 2.302

8.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Authors:  Evangelos Terpos; Gareth Morgan; Meletios A Dimopoulos; Matthew T Drake; Suzanne Lentzsch; Noopur Raje; Orhan Sezer; Ramón García-Sanz; Kazuyuki Shimizu; Ingemar Turesson; Tony Reiman; Artur Jurczyszyn; Giampaolo Merlini; Andrew Spencer; Xavier Leleu; Michele Cavo; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; G David Roodman
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

9.  Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma.

Authors:  Alvin C Ng; Shaji K Kumar; S Vincent Rajkumar; Matthew T Drake
Journal:  Am J Hematol       Date:  2009-07       Impact factor: 10.047

Review 10.  Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.

Authors:  Vanessa Innao; Alessandro Allegra; Lia Ginaldi; Giovanni Pioggia; Massimo De Martinis; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.